TCL Archive Litton Loses To PRI On Largest Frederick Contract, Competing Against Hopkins For Science Program August 27, 1982
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
